

Post-Consolidation Capital Structure

Melbourne, Australia; 18 January 2017: Further to Mach7 Technologies Limited's (the **Company**) announcement dated 16 January 2017 about its recent consolidation, the Company sets out below details on its post-consolidation capital structure and terms of its consolidated options and performance shares on issue.

The Company confirms that the record date for the consolidation was **12 January 2017**.

Fully paid ordinary shares	
No escrow restrictions	67,739,871
Escrowed until 1 June 2017	339,850
Escrowed until 1 July 2017	57,690
Escrowed until 18 February 2017	5,874,817
Escrowed until 8 April 2017	44,193,300
TOTAL ORDINARY SHARES ON ISSUE	118,205,528

Options to acquire ordinary shares	
Options exercisable at \$0.50, expiring 6 February 2017	4,289,245
▪ No escrow restrictions	2,995,260
▪ Escrowed until 18 February 2017	1,293,985
Options exercisable at \$1.00, vesting on 8 April 2017 and expiring 8 April 2020	100,000
Options exercisable at \$1.00, vesting on 8 April 2018 and expiring 8 April 2021	475,000
Options exercisable at \$1.00, vesting on 9 Dec 2018 and expiring 9 Dec 2021	125,000
TOTAL OPTIONS ON ISSUE	4,989,245

Performance shares	
No escrow restrictions	1,143,261
Class A Performance Shares	571,632
Class B Performance Shares	190,543
Class C Performance Shares	190,543
Class D Performance Shares	190,543
Escrowed until 8 April 2017	28,856,738
Class A Performance Shares	14,428,370
Class B Performance Shares	4,809,456
Class C Performance Shares	4,809,456
Class D Performance Shares	4,809,456
TOTAL PERFORMANCE SHARES ON ISSUE	29,999,999

Terms of Performance Shares (post- consolidation)**▪ Class A Performance Shares**

Subject to vesting milestone that the annual reported gross revenue attributable to the Mach7 Group is equal to or exceeds US\$6,000,000 for calendar year (**CY**) 2016 and the volume weighted average price (**VWAP**) of the Company's ordinary shares for any 20-day period during CY16 is equal to or exceeds \$2.00 (on a post-consolidation basis).

Where the Class A Performance Shares have not converted into ordinary shares during CY16, that the annual reported gross revenue attributable to the Mach7 Group is equal to or exceeds US\$6,600,000 for CY17 and the VWAP of the Company's ordinary shares for any 20-day period during CY17 is equal to or exceeds \$2.00 (on a post-consolidation basis).

▪ Class B Performance Shares

Subject to vesting milestone that the annual reported gross revenue attributable to the Mach7 Group is equal to or exceeds US\$6,000,000 for CY16 and the VWAP of the Company's ordinary shares for any 20-day period during CY16 is equal to or exceeds \$2.50 (on a post-consolidation basis).

Where the Class B Performance Shares have not converted into ordinary shares during CY16, that the annual reported gross revenue that is attributable to the Mach7 Group is equal to or exceeds US\$6,600,000 for CY17 and the VWAP of the Company's ordinary shares for any 20-day period during CY17 is equal to or exceeds \$2.50 (on a post-consolidation basis).

▪ Class C Performance Shares

Subject to vesting milestone that the annual reported gross revenue attributable to the Mach7 Group is equal to or exceeds US\$12,000,000 for CY16.

▪ Class D Performance Shares

Subject to vesting milestone that the annual reported gross revenue attributable to the Mach7 Group is equal to or exceeds US\$20,000,000 for CY17.

- ENDS

Contacts:

Jenni Pilcher
CEO Australia, CFO
+61 3 9646 2222 (Australia)
jenni.pilcher@mach7t.com

Alyn Tai
Company Secretary
+61 3 9286 7500 (Australia)
alyn.tai@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced [clinical viewing](#) and optimised [vendor neutral archiving](#) solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au